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ABSTRACT  
Objective: The current work is intended towards the development of a novel, simple and precise high-performance thin layer 
chromatographic (HPTLC) method coupled with a densitometer for the estimation of teriflunomide (TEF) present in the marketed 
formulation. 
Methods: The chromatographic development was performed on aluminum plates coated with silica gel 60 F254 
Results: Well separated band was observed with Rf value 0.46. The calibration curve plotted in the concentration range 100-700ng/band exhibited 
an excellent linear relationship with the r
using toluene: ethyl acetate: glacial 
acetic acid (7.5:2: 0.5 v/v/v) as the mobile phase. Densitometric scanning was achieved at the absorbance maxima, UV 284 nm. 
2
Conclusion: The method ensures minimal use of mobile phase with minimal run time compared to other reported analytical methods. This 
validated method can be used by quality control laboratories for the routine quantitative analysis of tablets consisting of Teriflunomide. 
 value of 0.9928. The method was found to comply with all the validation parameters as per the ICH 
guidelines. 
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Teriflunomide (fig. 1) (TEF) is an orally administered, second-
generation immunosuppressive/immunomodulatory agent which is 
an active metabolite of Leflunomide. It acts by inhibiting 
dihydroorotate dehydrogenase, an enzyme which is responsible for 
pyrimidine de novo synthesis [1-4]. It is permitted by both the US 
Food and Drug Administration (FDA) and the European Medicines 
Agency (EMA) as a disease-modifying therapy (DMT’s) for adults 
with relapsing-remitting multiple sclerosis (RRMS). This drug, not 
official any pharmacopeias like IP, USP and BP.  
 
 
Fig. 1: Teriflunomide 
 
The literature survey disclosed various methods for the estimation 
of TEF in API, marketed formulations and biological fluids. The 
detailed information on the various methods available are as 
follows; chromatographic methods such as HPLC [5, 6], UPLC [7], 
RP-HPLC [8, 9], LC-MS [10-13]. In all the reported techniques, the 
overall solvent consumption, cost per analysis and overall time 
required for analysis were much more. Furthermore, No HPTLC 
method has been reported so far, for the estimation of TEF in the 
marketed formulation. Therefore, the current work is directed 
towards the development of a novel HPTLC method for the 
determination of TEF in the marketed formulation having sensitivity 
in terms of nanogram with minimal development time, minimal use 
of solvents and its validation according to ICH guidelines. 
MATERIALS AND METHODS  
Materials and reagents 
Teriflunomide pure drug (API) was procured as a gift sample from 
Glenmark Ltd., Noida. All the other reagents used were of analytical 
grade and were procured from Merck specialties, private limited, 
Mumbai, India. Marketed Formulation (Denopsy tablets, Natco 
Pharma, Hyderabad) was purchased from a local pharmacy.  
HPTLC instrumentation and chromatographic conditions  
CAMAG HPTLC system equipped with Linomat 5 sample applicator 
operated under a gentle stream of nitrogen, coupled with a 100 µl 
HAMILTON syringe and a CAMAG TLC scanner 3controlled by 
winCATS software was used for the application and detection of 
spots respectively. Aluminum sheets having a dimension of 20×10 
cm, coated with silica gel 60 F254 
Preparation of standard solutions  
procured from Merck, Germany and 
a CAMAG twin trough TLC chamber having a dimension 27.0 cm 
width × 26.5 cm height × 7.0 cm was used for the chromatographic 
development. 
For chamber saturation, 20 ml of the mobile phase was transferred 
into the development tank with the lid closed. The assembly was 
kept aside for 20 min under room temperature. The plates were air 
dried using an air dryer after the application of spots and after the 
development, prior to densitometric scanning. The chromatographic 
conditions were as described in table 1. 
A stock solution containing 1000 ng/µl of TEF was prepared by 
using acetonitrile as a diluent. 0.5 ml of this solution was pipetted 
out into a 10 ml volumetric flask and the volume was made up, to get 
a working solution consisting of 50 ng/µl of TEF. 
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Table 1: HPTLC Chromatographic conditions 
Parameters Values 
Mobile phase Toluene: Ethyl acetate: Glacial acetic acid (7.5:2: 0.5 v/v/v) 
The volume of mobile phase used  20 ml 
Chamber saturation time 20 min 
Band length 6 mm 
Dosage speed  150 nl/s 
Distance between bands 10 mm 
Development time  7 min 
Detector wavelength 284 nm 
Rf value 0.46 
 
Preparation of sample solution (Formulation) 
As specified in the label, each tablet contains 14 mg of TEF. The 
weight of 10 tablets was noted and crushed using a mortar and 
pestle, the quantity of powder equivalent to 10 mg of teriflunomide 
was transferred to a 10 ml volumetric flask and the volume was 
made up with acetonitrile. The required dilutions were made to get a 
final concentration of 50 ng/µl. 
Method validation 
The method was validated according to ICH guidelines for the following 
parameters: Linearity, accuracy, precision, the limit of detection (LOD) 
and limit of quantification (LOQ), specificity and robustness [14-16]. 
RESULTS AND DISCUSSION 
Optimization of chromatographic conditions 
The ideal mobile phase of the method was selected after several 
experimental trials. Solvents like acetonitrile, methanol, toluene, ethyl 
acetate used initially; did not provide a clear spot. Therefore, various 
permutations and combinations of these solvents were used for the 
trials. Out of all the combinations, toluene and ethyl acetate was found 
to give a spot. For better resolution, 0.5% glacial acetic acid was added. 
Thus, the final chromatographic condition, toluene: ethyl acetate: 
glacial acetic acid in the ratio 7.5: 2: 0.5 (v/v/v) was able to achieve a 
clear spot with good Rf value. Increasing the volume of glacial acetic 
acid leads to an increase in the Rf 
The wavelength for the densitometric scanning of the spots was 
selected after obtaining the UV spectra of TEF (fig. 2), which showed 
the maximum absorbance at 284 nm. 
value and vice versa. The chamber 
saturation time was found to show a similar effect. 
Linearity 
The calibration curve (fig. 3) was plotted between peak areas versus 
concentration. The linearity of TEF was constructed by applying 7 bands 
in the concentration range of 100-700 ng/band. The regression equation 
(r2= 0.9928) demonstrated the good linearity of the method. The slope 
and intercept of the regression equation were 15.471 and 3505.7 
respectively for TEF. The linearity was found to be satisfactory and 
reproducible. The calibration curve of linearity and overlay densitogram 
of TEF is depicted in fig. 3 and 4 respectively. 
  
 
Fig. 2: Overlay UV absorption spectra of TEF standard and formulation 
 
 
Fig. 3: Calibration curve of TEF 
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Fig. 4: Overlay densitogram of TEF 
 
Accuracy 
Accuracy was assessed in terms of percentage recovery, by 
spiking the band of the formulation with 50%, 100%, 150% of 
pure drug and then finding out the amount of the drug 
recovered. The mean percentage of recovery was found to be 
99%, as depicted in table 2. 
 
Table 2: Accuracy study of TEF 
Level of recovery 
(%) 
Amount of formulation 
(ng/band) 
Amount of pure drug (ng/band) % Recovery Mean % RSDa 
50 
 




100 50 98.04 0.668 
100 50 99.60  
100 
 




100 100 99.80 0.287 
100 100 99.40  
150 
 




100 150 98.00 0.721 




Mean for three independent analyses, SD=Standard deviation, RSD=Relative standard deviation 
Intraday and interday precision of the method was assessed by 
developing the plate after application of 6 replicates of the highest 
concentration on the TLC plate on the same day and the consecutive 
day respectively. Precision was reported in terms of %RSD. The 
%RSD values were found to be less than 2% as depicted in table 3, 
indicating the high precision of the developed method. 
 
Table 3: Precision study of TEF 
Precision studies Intraday Interday 
Conc. (ng/band) 700 700 
Average peak area (n=6) 13830.5 13734.17 
Standard deviation 101.8361 124.8431 
% RSD 0.7363 a 0.9089 
aMean for six independent analyses, SD=Standard deviation, RSD=Relative standard deviation. 
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Limit of detection and limit of quantitation 
LOD and LOQ were calculated with the aid of standard deviation (σ) 
and slope (s) from the calibration curve (n=3), by using the formula 
LOD = 3.3 σ/s and LOQ = 10 σ/s. LOD and LOQ of TEF were found to 
be 21 ng/band and 65 ng/band respectively, which indicates the 
good sensitivity of the method towards the analyte. 
Specificity 
The specificity of the method was assessed by comparing the UV 
absorption spectra (fig. 2) and densitogram of standard (fig. 4) TEF 
with the formulation (fig. 5). The densitogram of both standard and 
formulation showed the same Rf
Robustness 
 value indicating the good 
specificity of the method. 
The robustness was assessed by making small but deliberate 
changes in the method parameters such as; mobile phase ratio, 
chamber saturation time, scanning wavelength and finding out its 
effect on the peak area by calculating %RSD. The % RSD was found 
to be within 2%, which indicates the reliability of the method. The 
robustness of the method are depicted in table 4. 
 
Table 4: Robustness study of TEF 
Parameters % RSDa 
Mobile phase composition (±2 ml) 1.35 
Chamber saturation time (±2 min) 0.98 
Scanning wavelength (±2 nm) 1.72 
a
 
Analysis of formulation 
Mean for five independent analyses, SD=Standard deviation, RSD=Relative standard deviation. 
The % of a drug found in the formulation of the currently developed 
method was found to be 98.9%. The densitogram obtained from the 
formulation (fig. 5) exhibited a single spot at Rf
 
 0.46 without any 
interference of the excipients. The close agreement of the percentage 
of the drug found with label claims depicted the application of this 
method for the routine analysis of TEF present in its formulation.
 
Fig. 5: Densitogram of the formulation 
 
DISCUSSION 
A novel, simple and precise high-performance thin layer 
chromatographic (HPTLC) method coupled with densitometer was 
developed for the estimation of TEF present in the marketed 
formulation. There are some HPLC methods [7, 8] reported in the 
literature, but they have certain restrictions like require a large 
quantity of sample and/or organic solvents or sensitive to 
microgram concentration. Few methods like Liquid 
chromatography-mass spectroscopy for determination TEF in 
human or animal plasma [9-12] etc. are found in the literature, but 
these methods are not preferred for routine analysis of TEF in bulk 
and formulation studies, because of the high cost of analytical 
technique and the skilled requirement for sample treatment. A 
detailed evaluation of the analytical method procedures discussed 
with the present method was given in table 1. Accuracy results 
displayed good reproducibility with % RSD values below 2. This was 
found to be accurate as percent recovery observed was high i.e. 
within the range of 98.6-98.94 %, suggesting that the proposed 
method showed good agreement between the standard and the 
observed values and demonstrate an adequate accuracy within the 
specified limits as shown in the table 2. Furthermore, detection limit 
depends upon the instrument sensitivity as low detection limits give 
high sensitivity. The LOD and LOQ of developed for HPTLC method 
was found to be 21ng/ml and 65ng/ml respectively confirms 
method is sensitive. Results of intra and inter-day precision studies 
were expressed as %RSD, the results were given in table 3. The low 
values of %RSD showed that the method is precise. The results of 
robustness are tabulated in table 4, the method is not altered by 
changing the method parameters like mobile phase composition, 
chamber saturation time and scanning wavelength which proves 
that the method is robust. In addition, the estimation of the 
marketed preparation of TEF with the validated methods showed 
that the drug contents separated with no interfering peaks 
generated by the excipients in the marketed formulation as shown in 
the fig. 5. The method is versatile and simple for the analysis TEF in 
pure and pharmaceutical formulations. The method was found to 
obey all the validation parameters as per the ICH guidelines. The 
method confirms minimal use of the mobile phase with a short run 
time compared to other reported analytical methods. This validated 
method can be used for quality control laboratories for the routine 
quantitative analysis of tablets consisting of TEF. 
Gurupadayya et al. 




A novel, simple, rapid and precise HPTLC method coupled with 
densitometer scanning has been developed for the determination of 
TEF in the marketed formulation. This validated method can be used 
by quality control laboratories for the routine quantitative analysis 
of tablets consisting of TEF. The additives used in this formulation 
were also not interfering with the analysis. The method ensures 
minimal use of mobile phase with minimal run time compared to 
other reported analytical methods. Non-requirement of skilled 
personnel to operate the instruments involved is an added 
advantage of this method. 
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